Maravai LifeSciences appoints Rajesh Asarpota as CFO effective June 30, 2025, succeeding Kevin Herde

MARAVAI LIFESCIENCES HOLDINGS, INC.

Rajesh Asarpota appointed EVP and CFO effective June 30, 2025; Kevin Herde transitions to advisory role through Jan 31, 2026.
Asarpota receives $550k base salary, 70% target bonus, $200k cash sign-on bonus, and equity awards (333,333 options, 500k RSUs, 750k PSUs).
Previous CFO Kevin Herde entitled to severance payments per May 2023 employment agreement upon signing separation agreement.
Company not reaffirming or withdrawing FY2025 guidance; will review during Q2 2025 earnings call in August.

item 5.02item 7.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.